PDE4 inhibitors together with TGF-beta1 resulted in augmented PGE(2) production together with increased expression of COX mRNA and protein. The present study supports the concept that PDE4 inhibitors may attenuate fibroblast activities that can lead to fibrosis and that PDE4 inhibitors may be particularly effective in the presence of TGF-beta1 ...

2023年8月3日 · PDE4 inhibitors, such as Roflumilast, prevent the breakdown of cAMP, while TGFβ modulates cAMP by altering the metabolism of PGE2. The effect of PDE4 inhibitors may have been mediated through a cAMP-stimulated protein kinase, and it depended on fibroblast production of PGE2 and TGFβ-induced PGE2 production.

2016年4月1日 · Prostaglandin E2 (PGE2) is an important modulator of the fibrotic changes that occur in pulmonary fibrosis and COPD. It is important to understand the mechanisms that regulate the initiation and desensitization of lung fibroblast responses to PGE2.

2021年1月22日 · The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we investigate if the modulation of the cytokine environment in lung cancer with IL‐2 or IL‐15 renders NK cells resistant to suppression by PGE2.

2025年3月14日 · To investigate the potential role of cAMP in PGE2's anti-inflammatory activity, we employed the PDE4 inhibitor Roflumilast to enhance intracellular cAMP levels. Our findings demonstrated that Roflumilast treatment significantly reduced LPS-induced TNF-α secretion and augmented the inhibitory efficacy of PGE2 on LPS-induced TNF-α secretion ...

2021年3月30日 · Since β1- and β2-adrenergic receptors regulate PDE4 recruitment differently, in this study, we focused on the cAMP degradation pathways of DP and EP2 receptors stimulated by PGD 2 or PGE 2.

These data identify a PDE4-mediated attenuation of PGE2 inhibitory signaling in normal fibroblasts that appears to be altered in COPD fibroblasts. These alterations may contribute to COPD pathogenesis and could provide novel therapeutic targets.

We investigated the effects of phosphodiesterase 3 (PDE3) and PDE4 inhibitors, which are cAMP degrading enzymes, on prostaglandin E2 (PGE2)-induced osteoclast formation. A PDE4 inhibitor decreased PGE2-induced osteoclast formation, whereas a PDE3 inhibitor did not, possibly due to the lack of PDE3 e …

2013年10月8日 · In the current study, we investigated the effect of a long-acting β -agonist (salmeterol) and a phosphodiesterase 4 (PDE4) inhibitor (cilomilast) on human lung fibroblast-mediated collagen gel contraction. Higher concentrations of salmeterol (10 −7 and 10 −6 M) inhibited fibroblast-mediated collagen gel contraction.

2022年9月13日 · Furthermore, it was shown that PDE4 inhibitor enhances PGE2-induced growth arrest of osteoclast formation. It has been found that the PDE4 inhibitor in one way promotes the formation of osteoblasts, and in another way, inhibits the formation of osteoclasts, both of which might may increase bone formation [ 121 ].